Fierce Pharma

NOVEMBER 23, 2022

price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line. Sporting a $3.5M Wed, 11/23/2022 - 10:10.

FDA 300

FDA 300

MedCity News

APRIL 26, 2024

million price tag, the same as a CSL Behring gene therapy already available for treating the inherited bleeding disorder. The post Pfizer’s First Gene Therapy Approval Sets Up a Showdown With CSL in Hemophilia B appeared first on MedCity News. The one-time treatment carries a $3.5

FDA 93

FDA Biopharma Pharma 93

Pharmaceutical Technology

NOVEMBER 9, 2022

Despite their potential multi-million-dollar sticker price, if haemophilia treatments by BioMarin and CSL Behring prove durable, they could help patients save money compared to current treatments, experts note. A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96 million ($1.8

Safety 111

Safety Pharmaceutical Patients Medicine 111

Pharmaceutical Technology

FEBRUARY 10, 2023

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 This is not the first treatment to come with a high price tag.

Marketing 105

Marketing Medicine Leads Safety 105

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Medicine 52

Pharmaceutical Technology

JUNE 21, 2023

CSL announced the first patient with haemophilia B has been treated with its recently approved gene therapy Hemgenix (etranacogene dezaparvovec). The high price tag may be hard to defend , but with lifetime treatment costs for haemophilia B reaching as high as $23m for some, the single-dose treatment could prove far more cost-effective.

Patients 98

Patients Food and Drug Administration Engineering Sales 98

pharmaphorum

NOVEMBER 16, 2022

However, with a price tag of €1.58 However, a recently released report from the organisation could blow the price tag of Zolgensma out of the water. In guidance for CSL Behring’s etranacogene dezaparvovec, the ICER’s assessment found that the potential treatment could be fairly priced at $2.93-$2.96 At more than $2.1

Medicine 125

Medicine Marketing Healthcare Healthcare 125